glp 1 and perimenopause GLP-1 Microdosing for Perimenopause: Benefits & Risks GLP-1 Microdosing for Perimenopause and

GLP-1 agonists, such as liraglutide and semaglutide, are increasingly used in medical weight loss due to their ability to mimic the natural hormone glucagon-like peptide-1, which is, for the most part, responsible for regulating appetite and food intake

In many cases, however, the GLP-1 drugs are being compounded in pharmacies that are not required to meet these good manufacturing requirements

The two types of incretin hormones that have critical roles in incretin signaling, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), bind to specific members of the G-protein-coupled receptor (GPCR) family: the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR), respectively

Keywords: ozempic, semaglutide, wegovy, rybelsus, lactation, breastfeeding, pharmacology, GLP-1 receptor, GLP-1 analogue, infant risk 1

Intriguingly, a blockade of central estrogen receptors reduces the effect of a GLP-1R analog (exendin-4) on food-motivated behavior in both sexes, indicating that estrogen may modulate the effects of GLP-1 analogs not only in females but also in males (40)